Saniona (SANION) R&D Day 2026 summary

Pipeline overview and program updates

• SAN2668 highlighted as a novel treatment candidate for severe pediatric epilepsies, with a focus on developmental and epileptic encephalopathies.

• Internal pipeline also includes SAN2219 for epilepsy and SAN2465 for major depressive disorder.

Clinical trial data and development milestones

• Planned Phase 1 clinical development strategy for SAN2668 will be discussed at the upcoming R&D Day.

• Key preclinical data supporting SAN2668's development will be reviewed during the event.

R&D strategy and innovation priorities

• Ion channel discovery platform underpins the pipeline and is validated through multiple research collaborations.

• Series of webinars planned to highlight differentiated CNS pipeline assets.